August 29, 2019 09:02 AM EDTUpdated 09:37 AM
R&D

Ab­b­Vie’s $10B Ro­va-T play ends in one last fail­ure — R&D team shuts it all down

John Carroll

Editor & Founder

Ab­b­Vie’s Ro­va-T has failed its last clin­i­cal tri­al.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Trump blog: FDA, NIH picks clear Sen­ate pan­el; FDA top lawyer re­signs

Up­dat­ed: White House pulls Wel­don's nom­i­na­tion to lead CDC at last minute

MeiraGTx teams with cryp­tic AI start­up, co-found­ed by Er­ic Schmidt, to ad­vance Parkin­son's gene ther­a­py

Up­dat­ed: En­do and Mallinck­rodt to merge in $6.7B deal

Ace­lyrin, Pli­ant turn to ‘poi­son pill’ as Kevin Tang’s Con­cen­tra pur­sues both com­pa­nies

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times